News Articles

- News Articles
BioSpace | February 04, 2026

From Awareness to Acceleration: Rare Disease Drug Development Enters a Pivotal Era
Read More
- News Articles
Genetic Engineering & Biotechnology News | January 13, 2026

Fast-Tracked CGT Platform Eliminates Patient Preconditioning

Immusoft’s MPS 1 CGT therapeutic hurdles traditional barriers, eliminating patient preconditioning and enabling redosing
Read More
- News Articles
Citeline | February 27, 2025

Immusoft Goes For Cell Therapy Plan ‘B’
Read More
- News Articles
Genetic Engineering & Biotechnology News | October 17, 2024

Immusoft Reports Promising Early Data for Lead Candidate in MPS I

First patient dosed with ISP-001 shows reduced urinary GAG level, functional improvements surpassing enzyme replacement therapy in Phase I trial
Read More
- News Articles
Endpoints News | October 15, 2024

First patient who received engineered B cell therapy sees early promise for MPS I
Read More
- News Articles
Nature Biotechnology | June 17, 2024

B cells as drug factories
Read More
- News Articles
Wired | December 16, 2023

In a World First, a Patient’s Antibody Cells Were Just Genetically Engineered
Read More
- News Articles
MIT Technology Review | September 01, 2022

A new gene therapy based on antibody cells is about to be tested in humans

Genetically-engineered B cells, the cells that make our bodies' antibodies, will be harnessed to treat a rare disease.
Read More
- News Articles
Bloomberg | October 13, 2021

Takeda to Work With Immusoft in $900 Million Rare-Disease Deal
Read More
- News Articles
Endpoints News | October 13, 2021

Drawn to the idea of turning B cells into ‘protein factories,’ Takeda jumps into a milestone-heavy, $900M pact

Fierce Biotech
Read More